European Teratology Information Services Study (BMJ 2024) Design: Prospective observational cohort Sample: 168 GLP-1 RA-exposed pregnancies, compared with diabetic and obese reference groups Findings: Major birth defect rates: 2.6% (GLP-1 RA) vs
Zepbound's list price is approximately $1,060 per month
Whilst the US Food and Drug Administration (FDA) has approved five drug therapies to treat obesity (orlistat, phentermine/topiramate, lorcaserin, naltrexone/bupropion, liraglutide), the European Medicines Agency (EMA) has approved only three drug therapies (orlistat, bupropion/naltrexone and liraglutide) [8] at the time of writing
An early appointment reduces the length of fasting required, helping maintain stable blood sugar levels
Using PSM on age at index, BMI, metformin and statin exposure, BRCA mutation status, hormonal contraceptive use, parity, breastfeeding history, and smoking status, they identified 2 balanced cohorts: 74,354 GLP-1 RAexposed women and 74,355 controls (total n = 148,709)